Strategies for global prevention of hepatitis B virus infection

Advances in Experimental Medicine and Biology

Volumn 659, Issue , 2010, Pages 175-188

  Damme, Pierre Van ^a   Zanetti, Alessandro R ^a   Shouval, Daniel ^a   Herck, Koen Van ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE;

ABDOMINAL PAIN; ARTICLE; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ENDEMIC DISEASE; FATIGUE; HEPATITIS B; HUMAN; INCIDENCE; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE SWELLING; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; MASS IMMUNIZATION; MORTALITY; NAUSEA; PRIORITY JOURNAL; VIRUS TRANSMISSION; DISEASE TRANSMISSION; GENETICS; HEALTH; HEPATITIS B VIRUS; IMMUNIZATION; IMMUNOLOGY; ISOLATION AND PURIFICATION; REVIEW; VIROLOGY;

HEPATITIS B VIRUS;

HEPATITIS B; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; IMMUNIZATION; WORLD HEALTH;

EID: 77950345152     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-0981-7_14     Document Type: Article

References (59)

1. Banatvala, J.E., & Van Damme, P. (2003). Hepatitis B vaccine-do we need boosters? J Hepatol, (10), 1-6.
2. Banatvala, J.E., Van Damme, P., & Emiroglu, N. (2006). Hepatitis B immunization in Britain: time to change? BMJ, (332), 804-805. (Pubitemid 44365611)
3. Bonanni, P., Pesavento, G., Bechini, A., Tiscione, E., Mannelli, F., Benucci, C., & Nostro, A.L. (2003). Impact of universal vaccination programmes on the epidemiology of hepatitis B: 10 years of experience in Italy. Vaccine, (21), 685-691.
4. Centers for Disease Control and Prevention 1987 (1987). Recommendations of the immunization practices advisory committee. Update on hepatitis B prevention. Morbid Mortal Weekly Report, (36), 353-360.
5. Chan, C.Y., Lee, S.D., & Lo, K.J. (2004). Legend of hepatitis B vaccination: the Taiwanese experience. J Gastroenterol Hepatol, (19), 121-126.
6. Chen, C.-J., Yang, H.-I., Su, J., Jen, C.-L., You, S.-L., Lu, S.-N., Huang, G.-T. et al. (2006). Risk of HCC across a biological gradient of serum HBV-DNA levels. JAMA, (295), 65-73.
7. Coursaget, P., Leboulleux, D., Soumare, M., le Cann, P., Yvonnet, B., Chiron, J.P. et al. (1994). Twelve-year follow-up study of hepatitis B immunisation of Senegalese infants. J Hepatol, (21), 250-254.
8. Da Villa, G., Romanò, L., Sepe, A., Iorio, R., Parimbello, N., Zappa, A., & Zanetti, A.R. (2007). Impact of hepatitis B vaccination in high endemic area of south Italy and longterm duration of anti-HBs antibody in two cohort of vaccinated individuals. Vaccine, (25), 3133-3136. (Pubitemid 46482751)
9. Dienstag, J.L.,Werner, B.G., Polk, B.F., Snydman, D.R., Craven, D.E., & Platt, R. (1984). Hepatitis B vaccine in health care personnel: safety, immunogenicity, and indicators of efficacy. Ann Intern Med, (82), 8168-8172.
10. Duclos, P. (2003). Safety of immunization and adverse events following vaccination against hepatitis B. J Hepatol, (39), 83-88.
11. EUROHEP.NET (2004). Data on surveillance and prevention of hepatitis A and B in 22 countries, 1990-2001. Antwerp; (also available on www.eurohep.net)
12. European Consensus Group on Hepatitis B immunity (2000). Are booster immunisations needed for lifelong hepatitis B immunity? Lancet, (355), 561-565.
13. Erhardt, A., Blondin, D., Hauck, K., Sagir, A., Kohnle, T., Heintges, T., & Häussinger, D. (2005). Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut, (54), 1009-1013. (Pubitemid 40873918)
14. Francois, G., Hallauer, J., & Van Damme, P. (2002). Hepatitis B vaccination: how to reach risk groups. Vaccine, (21), 1-4. (Pubitemid 35351344)
15. Gaeta, G.B., Stroffolini, T., Chiaramonte, M., Ascione, T., Stornaiuolo, G., Lobello, S., Sagnelli, E. et al. (2000). Chronic hepatitis D: a vanishing disease? An Italian multicenter study. Hepatology, (32), 824-827.
16. Goldstein, S.T., Zhou, F., Hadler, S.C., Bell, B.P., Mast, E.E., & Margolis, H.S. (2005). A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol, (34), 1329-1339. Available at: http://aim.path.org/en/vaccines/hepb/ assessBurden/model/index. html (retrieved on 3 October 2008).
17. Hadler, S.C. & Margolis, H.S. (1992). Hepatitis B immunization: vaccine types, efficacy, and indications for immunization. In: Topics In Infectious Diseases. J.S. Remington, & M.N. Swartz (Eds.). (Vol. 12). Boston: Blackwell Scientific Publications, pp. 282-308.
18. Hahné, S., Ramsay, M., Balogun, K., Edmunds, W.J., & Mortimer, P. (2004). Incidence and routes of transmission of hepatitis B virus in England and Wales, 1995-2000: implications for immunisation policy. J Clin Virol, (29), 211-220. (Pubitemid 38281210)
19. Hollinger, F.B. (1989). Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines and vaccine protocol recommendations. Am J Med, 87(Suppl 3A), 36-40.
20. Jilg, W., Schmidt, M., Zachoval, R., & Deinhardt, F. (1984). Hepatitis B vaccination: how long does protection last? Lancet, (2), 458. (Pubitemid 14059406)
21. Jilg, W., Schmidt, M., & Deinhardt, F. (1988). Persistence of specific antibodies after hepatitis B vaccination. J Hepatol, (6), 201-207.
22. Kao, J.-H. & Chen, D.S. (2005). Hepatitis B vaccination: to boost or not to boost? Lancet, (366), 1337-1338. (Pubitemid 41443389)
23. Keating, G.M. & Noble, S. (2003). Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B. Drugs, (63), 1021-1051. (Pubitemid 36575466)
24. Kretzschmar, M. & de Wit, A. (2008). Universal hepatitis B vaccination. Lancet, (8), 85-87.
25. Lavanchy, D. (2004). Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat, (11), 97-107. (Pubitemid 38365759)
26. Lavanchy, D. (2005). Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol, 34(Suppl 1), 1-3.
27. Lok, A.S.F. & McMahon, B.J. (2007). Chronic hepatitis B: AASLD practice guidelines. Hepatology, (45), 507-539.
28. Mahoney, F.J. (1999). Update on diagnosis, management and prevention of hepatitis B virus infection. Clin Microbiol Rev, (12), 351-366. (Pubitemid 29196857)
29. Ng, K.P., Saw, T.L., Baki, A., Rozainah, K., Pang, K.W., & Ramanathan, M. (2005). Impact of expanded programme on immunization against hepatitis B infection in school children in Malaysia. Med Microbiol Immunol, (194), 163-168. (Pubitemid 41202533)
30. Niu, M.T. (1996). Review of 12 million doses shows hepatitis B vaccine safe. Vaccine Weekly, (4), 13-15.
31. Perz, J.F., Elm, J.L., Jr., Fiore, A.E., Huggler, J.I., Kuhnert, W.L., & Effler, P.V. (2006). Near elimination of hepatitis B infections among Hawaii elementary school children universal infant hepatitis B vaccination. Pediatrics, (118), 1403-1408. (Pubitemid 46393784)
32. Piazza, M., Da Villa, G., Picciotto, L., Abrescia, N., Guadagnino, V., Memoli, A.M., Vegnente, A. et al. (1988). Mass vaccination against hepatitis B in infants in Italy. Lancet, (332), 1132.
33. Pollard, A.J. (2007). Hepatitis B vaccination. BMJ, (335), 950.
34. Rendi-Wagner, P., Shouval, D., Genton, B., Lurie, Y., Rumke, H., Boland, G., Cerny, A. et al. (2006). Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine. Vaccine, (24), 2781-2789.
35. Romanò, L., Mele, A., Pariani, E., Zappa, A., & Zanetti, A. (2004). Update in the universal vaccination against hepatitis B in Italy: 12 years after its implementation. Eur J Public Health, 14(Suppl), S19.
36. Safary, A. & André, F. (1999). Over a decade of experience with the yeast recombinant hepatitis B vaccine. Vaccine, (18), 57-67.
37. Shaefer, S. (2005). Hepatitis B virus: significance of genotypes. J Viral Hepat, (12), 111-124.
38. Shepard, E.W., Simard, E.P., Finelli, L., Fiore, A.E., & Bell, B.P. (2006). Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev, (28), 112-125. (Pubitemid 44289094)
39. Sherlock, S. (1993). Clinical features of hepatitis. In: Viral Hepatitis. A.J. Zuckerman, H.S. Thomas (Eds.). London: Churchill Livingstone, pp. 1-11.
40. Shouval, D., Ilan, Y., Adler, R., Deepen, R., Panet, A., Even-Chen, Z., Gorecki, M. et al. (1994). Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines. Vaccine, (12), 1453-1459.
41. Szmuness, W., Stevens, C.E., Zang, E.A., Harley, E.J., & Kneller, A. (1981). A controlled clinical trial of the efficacy of the hepatitis B vaccine (Hepatavax B): a final report. Hepatology, (5), 377-385. (Pubitemid 12218155)
42. Tan, J. & Lok, A.S.F. (2007). Update on viral hepatitis: 2006. Gastroenterology, (23), 263-267. (Pubitemid 46573141)
43. Tandon, B.N. & Tandon, A. (1997). Epidemiological trends of viral hepatitis in Asia. In: Viral Hepatitis and Liver Disease. M. Rizzetto, R.H. Purcell, J.L. Gerin, & G. Verme (Eds.). Turin: Edizioni Minerva Medica, pp. 559-661.
44. Tilson, L., Thornton, L., O'Flanagan, D., Johnson, H., & Barry, M. (2008). Cost-effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation. Eur J Public Health, 18(3), 275-282. (Pubitemid 351786636)
45. Van Damme, P., Kane, M., & Meheus, A. (1997). Integration of hepatitis B vaccination into national immunisation programmes. BMJ, (314), 1033-1037.
46. Van Damme, P., Van Herck, K., Leuridan, E., & Vorsters, A. (2004). Introducing universal hepatitis B vaccination in Europe: differences still remain between countries. Eurosurveillance Weekly, (9), 67-68.
47. Van Damme, P. & Van Herck, K. (2007). A review of the long-term protection after hepatitis A and B vaccination. Travel Med Infect Dis, (5), 79-84. (Pubitemid 46211211)
48. van der Eijk, A.A., Niesters, H.G.M., Götz, H.M., Janssen, H.L.A., Schalm, S.W., Osterhaus, A.D.M.E., & de Man, R.A. (2004). Paired measurements of quantitative hepatitis B virus DNA in saliva and serum of chronic hepatitis B patients: implications for saliva as infectious agent. J Clin Virol, (29), 92-94. (Pubitemid 38121578)
49. van Houdt, R., Sonder, G.J., Dukers, N.H., Bovee, L.P., van den Hoek, A., Coutinho, R.A., & Bruisten, S.M. (2007). Impact of targeted hepatitis B vaccination program in Amsterdam, the Netherlands. Vaccine, (25), 2698-2705. (Pubitemid 46400923)
50. Venters, C., Graham, W., & Cassidy, W. (2004). Recombivax-HB: perspectives past, present and future. Expert Rev Vaccines, (3), 119-129. (Pubitemid 38470522)
51. Viviani, S., Jack, A., Hall, A.J., Maine, N., Mendy, M., Montesano, R., & Whittle, H.C. (1999). Hepatitis B vaccination in infancy in the Gambia: protection against carriage at 9 years of age. Vaccine, (17), 2946-2950. (Pubitemid 29366973)
52. Wainwright, R., Bulkow, L.R., Parkinson, A.J., Zanis, C., & McMahon, B.J. (1997). Protection provided by hepatitis B vaccine in a Yupik Eskimo Population: results of a 10 year study. J Infect Dis, (175), 674-677. (Pubitemid 27086173)
53. West, D.J. & Calandra, G.B. (1996). Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine, (14), 1019-1027. (Pubitemid 26281288)
54. Whittle, H.C., Maine, N., Pilkington, J.,Mendy,M., Fortuin, M., Bunn, J., Allison, L. et al. (1995). Long-term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages. Lancet, (345), 1089-1092.
55. World Health Organization 1992. (1992). Informal consultation on quadrivalent diphtheria-tetanuspertussis- hepatitis B vaccine. Final Report, pp.1-12, Geneva.
56. World Health Organization (2004). Hepatitis B vaccines (WHO position paper). Weekly Epidemiol Record, (79), 255-263.
57. World Health Organization 2006. Vaccines and biologicals. WHO vaccine preventable disease monitoring system. Global summary 2006 (data up to 2005). Available at http://www.who.int/vaccines-documents/GlobalSummary.pdf (retrieved on 15 September 2007).
58. Zanetti, A.R., Tanzi, E., Romanò, L., & Grappasonni, I. (1993). Vaccination against hepatitis B: the Italian strategy. Vaccine, (11), 521-524. (Pubitemid 23130856)
59. Zanetti, A.R., Mariano, A., Romanò, L., D'Amelio, R., Chironna, M., Coppola, R.C., Cuccia, M., Mangione, R., Marrone, F., Negrone, F.S., Parlato, A., Zamparo, E., Zotti, C., Stroffolini, T., & Mele, A; Study Group. (2005). Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet, 366(9494), 1379-1384. (Pubitemid 41443405)